ExpreS2ion ilmoitti tänään, että sen osakkuusyhtiö AdaptVac (jossa ExpreS2ionin omistusosuus on 34 %) on valittu johtamaan konsortiota, jolle on myönnetty 12,4 miljoonan USD:n avustus CEPI:ltä ja Euroopan unionin Horizon Europe -ohjelmasta. Avustus tukee uudenlaisen rokotteen kehittämistä, jonka on tarkoitus tarjota kokonaisvaltaisen suojan useita tappavia filoviruksia vastaan. Projektin odotetaan kestävän seuraavat viisi vuotta, sisältäen suunnitellut faasin I/II tutkimukset.

ExpreS2ion Biotech: Pipeline focus on HER2+ breast cancer therapy

Today, ExpreS2ion Biotechnologies’ CEO, Bent Frandsen, presented the results for the first quarter of 2025, provided further insights into the recent pipeline developments, and shared the latest updates on partnerships aimed at commercializing the company’s technology platform

ExpreS2ion Biotechnologies is expected to release its Q1 2025 results on 15 May 2025. Later on the same day at 10:30, the management will present the results and the achievements in an online live presentation. The presentation will be followed by a Q&A session.

ExpreS2ion has today announced that it will expand its ES2B-C001 study to include combination testing. This should increase the Clinical trial sites and patient population and could potentially increase commercial potential.

ExpreS2ion Biotech: Signs Letter of Intent with WuXi Vaccines to initiate technology evaluation of ExpreS2ion’s proprietary production platform ExpreS2™

ExpreS2ion has today informed the market about the progress on the HER2 breast cancer vaccine candidate, ES2B-C001, but also announced that they will no longer pursue the development of a CMV candidate, a collaboration with Evaxion Biotech.